LAG3 and classic Hodgkin lymphoma: LAG-3 expression in distinct tumor-infiltrating lymphocyte (TIL) subpopulations, particularly in tumors with low MHC-II expression, may be critical for the development of a tolerogenic immune environment in classic Hodgkin lymphoma (cHL).